Pipeline

We employ biologic-based approaches that are designed to enhance the ability of the patient’s own immune system to detect and destroy cancer cells. Our leading clinical programs, TTI-621 and TTI-622, are immune checkpoint inhibitors targeting CD47. We also have several discovery projects addressing novel immunologic targets.

Target

CD47 – Innate Immune Checkpoint

Candidate

TTI-621 (Intravenous)

Indication

B- and T-cell lymphomas, other blood cancers

PreclinicalClinical Proof-of-ConceptPivotal

Indication

T-cell lymphoma, Solid Cancers

PreclinicalClinical Proof-of-ConceptPivotal

Candidate

TTI-622

Indication

Lymphoma, Myeloma

PreclinicalClinical Proof-of-ConceptPivotal